v3.25.2
Revenues
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Revenues by Product Line. The following table represents total net revenues by product line (in thousands):
For the Three Months Ended June 30,For the Six Months Ended June 30,
2025202420252024
HIV$14,398 $13,652 $27,298 $27,032 
Sample Management Solutions (1)
9,855 12,609 18,965 23,431 
HCV4,126 4,734 8,459 7,734 
Risk Assessment Testing (2)
446 2,308 1,866 4,352 
Other product and services revenues (3)
994 897 1,767 1,429 
COVID-19 (4)
28 18,939 489 42,067 
Molecular Services— 810 — 1,683 
Net product and services revenues$29,847 $53,949 $58,844 $107,728 
Non-product and services revenues (5)
1,395 386 2,329 739 
Net revenues$31,242 $54,335 $61,173 $108,467 
(1)Includes Genomics, Microbiome and Colli-Pee® product revenues.
(2)Includes substance abuse testing product revenues.
(3)Includes Syphilis revenues.
(4)Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.
(5)Includes funded research and development contracts, royalty income and grant revenues.
Revenues by Geographic Area. The following table represents total net revenues by geographic area, based on the location of the customer (in thousands):
For the Three Months Ended June 30,For the Six Months Ended June 30,
2025202420252024
United States$19,852 $44,386 $40,187 $89,597 
Africa8,027 6,366 15,216 12,070 
Europe2,117 2,164 3,754 3,766 
Other regions1,246 1,419 2,016 3,034 
$31,242 $54,335 $61,173 $108,467 
Customer Concentration. The following table represents customer concentration risk:

For the Three Months Ended June 30,For the Six Months Ended June 30,
2025202420252024
Net Revenues
Non-commercial customer N/A33%N/A37%
June 30,December 31,
20252024
Accounts Receivable
Commercial customer19%10%
Vendor Concentration. The Company currently purchases certain products and critical components of its products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of its products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on its business, as well as its financial condition and results of operations.
Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2025 and December 31, 2024 was comprised of customer prepayments of $2.4 million and $3.0 million, respectively.
The following table represents deferred revenue recognized:
For the Three Months Ended June 30,For the Six Months Ended June 30,
Deferred Revenue Recognized2025202420252024
Accrued at beginning of period$974 $774 $1,461 $1,194